Salem Partners

OncoNano Medicine is a biotech company that develops nanotechnology-enabled fluorescent probes to help cancer surgeons visualize tumors during surgery, allowing them to excise tumors more precisely. The fluorescent sensor targets the different pH signals, thus making them glow so they are easier to distinguish from normal tissue. OncoNano Medicine is a UTSW spinoff company based in Dallas, Texas.

RightsLine Software, Inc. is a provider of rights and contract management software tailored for media and entertainment companies. Founded in 1999 and based in Beverly Hills, California, the company specializes in managing the full lifecycle of licensing and distribution deals. Its software suite includes the Rights Intelligence System, which centralizes rights information, the Rights Royalty Manager for processing royalties, and the Rights Portfolio Analyzer for real-time reporting. RightsLine's solutions enable clients to track licensing agreements, manage contract visibility, and optimize intellectual property assets across various industries such as film, television, music, and publishing. The platform leverages cloud technology to offer a user-friendly interface, accommodating libraries of any size and complexity. Clients range from major corporations like Disney and Google to smaller distributors, all benefiting from a streamlined process for managing rights and maximizing revenue from their content assets.

Lucid Sight, Inc. is a computer software company based in Los Angeles, California, that specializes in the design and development of virtual reality games and applications. Founded in 2015, the company focuses on creating immersive entertainment experiences using emerging technologies, including virtual reality, augmented reality, and blockchain. Lucid Sight develops innovative monetization and marketing platforms intended for brands and game developers, as well as tools and plug-ins for virtual reality developers. By leveraging these technologies, the company aims to enhance the gaming experience through engaging multiplayer adventure and sports games. Its products are available through a catalog that serves both developers and advertisers.

AsclepiX Therapeutics, Inc. is a biopharmaceutical company focused on the design and development of innovative treatments for diseases related to abnormal blood vessel growth, specifically through the use of short biomimetic anti-angiogenic and anti-lymphangiogenic peptides. The company's lead candidates, including AXT107, AXT201, AXT301, and AXT501, target conditions such as diabetic macular edema, wet age-related macular degeneration, and macular edema following retinal vein occlusion, which are among the leading causes of blindness. Additionally, AXT201, AXT301, and AXT501 are being explored for their potential in treating various solid tumors. AsclepiX leverages advanced computational biology, bioinformatics, and the latest developments in biomaterials to enhance drug delivery systems, aiming to create long-lasting biodegradable nanoparticles that can effectively deliver its therapeutic peptides. Incorporated in 2011 and based in Baltimore, Maryland, AsclepiX Therapeutics is committed to addressing unmet medical needs in ophthalmology, oncology, and other diseases driven by angiogenesis and lymphangiogenesis.

OncoNano Medicine is a biotech company that develops nanotechnology-enabled fluorescent probes to help cancer surgeons visualize tumors during surgery, allowing them to excise tumors more precisely. The fluorescent sensor targets the different pH signals, thus making them glow so they are easier to distinguish from normal tissue. OncoNano Medicine is a UTSW spinoff company based in Dallas, Texas.

Sebacia, Inc. is a medical device company based in Duluth, Georgia, specializing in light-based therapies for dermatological conditions, particularly acne. The company aims to provide innovative alternatives to traditional topical and systemic medications by utilizing a patented technology involving gold microparticles. These microparticles are applied to the skin and activated using a standard dermatology laser, selectively targeting the structures involved in acne. Developed in collaboration with researchers from Rice University and the Wellman Center of Photomedicine at Massachusetts General Hospital, Sebacia's approach addresses unmet needs in dermatology while offering a more effective treatment option for those affected by acne. Established in 2008, Sebacia continues to advance its technology with the goal of improving patient outcomes.

Lucid Sight, Inc. is a computer software company based in Los Angeles, California, that specializes in the design and development of virtual reality games and applications. Founded in 2015, the company focuses on creating immersive entertainment experiences using emerging technologies, including virtual reality, augmented reality, and blockchain. Lucid Sight develops innovative monetization and marketing platforms intended for brands and game developers, as well as tools and plug-ins for virtual reality developers. By leveraging these technologies, the company aims to enhance the gaming experience through engaging multiplayer adventure and sports games. Its products are available through a catalog that serves both developers and advertisers.

Femasys Inc. is a biomedical company dedicated to advancing women's healthcare through the research, development, and manufacture of medical devices primarily used in physician offices across the United States. Founded in 2004 and headquartered in Suwanee, Georgia, Femasys specializes in non-surgical female sterilization devices, infertility diagnosis tools, and cervical cancer screening technologies. Notable products include the FemVue Saline-Air Device, which aids in assessing fallopian tube health, and the FemChec Pressure Management Device, designed to regulate pressure during hysterosalpingograms. Additionally, the FemCerv device facilitates the collection of non-contaminated tissue samples for cervical cancer screening. Femasys aims to provide women with minimally invasive options that enhance patient care and improve health outcomes in underserved areas.

ZS Pharma, Inc. is a biopharmaceutical company based in Coppell, Texas, focused on developing non-absorbed drugs for renal, cardiovascular, liver, and metabolic diseases. Established in 2008, the company specializes in highly selective ion-trap therapies, particularly its lead candidate, ZS-9. This innovative treatment employs proprietary zirconium silicate technology to create ion traps that can effectively reduce excess potassium levels in patients suffering from hyperkalemia, a serious condition often associated with chronic kidney disease, hypertension, diabetes, and heart failure. ZS-9 is currently undergoing late-stage clinical trials to evaluate its efficacy and safety. As of December 2015, ZS Pharma operates as a subsidiary of Zeneca, Inc.

ZS Pharma, Inc. is a biopharmaceutical company based in Coppell, Texas, focused on developing non-absorbed drugs for renal, cardiovascular, liver, and metabolic diseases. Established in 2008, the company specializes in highly selective ion-trap therapies, particularly its lead candidate, ZS-9. This innovative treatment employs proprietary zirconium silicate technology to create ion traps that can effectively reduce excess potassium levels in patients suffering from hyperkalemia, a serious condition often associated with chronic kidney disease, hypertension, diabetes, and heart failure. ZS-9 is currently undergoing late-stage clinical trials to evaluate its efficacy and safety. As of December 2015, ZS Pharma operates as a subsidiary of Zeneca, Inc.